• Abstract and Figures
• Public Full-text

RANDOMISED EVALUATION OF COVID-19 THERAPY (RECOVERY) Background: In early 2020, as this protocol was being developed, there were no approved treatments for COVID-19, a disease induced by the novel coronavirus SARS-CoV-2 that emerged in China in late 2019. The UK New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) advised that several possible treatments should be evaluated, including Lopinavir-Ritonavir, low-dose corticosteroids, and Hydroxychloroquine (which has now been done). A World Health Organization (WHO) expert group issued broadly similar advice. These groups also advised that other treatments will soon emerge that require evaluation. Eligibility and randomisation: This protocol describes a randomised trial among patients hospitalised for COVID-19. All eligible patients are randomly allocated between several treatment arms, each to be given in addition to the usual standard of care in the participating hospital: No additional treatment vs colchicine vs corticosteroids (children only) vs intravenous immunoglobulin (children only). In a factorial design (in the UK alone), eligible patients are allocated simultaneously to no additional treatment vs convalescent plasma vs synthetic neutralising antibodies (REGN-COV2). Separately, all participants aged 18 years or older will be allocated to either aspirin vs control. The study allows a subsequent randomisation for patients with progressive COVID-19 (evidence of hyper-inflammatory state): No additional treatment vs tocilizumab. For patients for whom not all the trial arms are appropriate or at locations where not all are available, randomisation will be between fewer arms. Adaptive design: The interim trial results will be monitored by an independent Data Monitoring Committee (DMC). The most important task for the DMC will be to assess whether the randomised comparisons in the study have provided evidence on mortality that is strong enough (with a range of uncertainty around the results that is narrow enough) to affect national and global treatment strategies. In such a circumstance, the DMC will inform the Trial Steering Committee who will make the results available to the public and amend the trial arms accordingly. Regardless, follow-up will continue for all randomised participants, including those previously assigned to trial arms that are modified or ceased. New trial arms can be added as evidence emerges that other candidate therapeutics should be evaluated. Outcomes: The main outcomes will be death, discharge, need for ventilation and need for renal replacement therapy. For the main analyses, follow-up will be censored at 28 days after randomisation. Additional information on longer term outcomes may be collected through review of medical records or linkage to medical databases where available (such as those managed by NHS Digital and equivalent organisations in the devolved nations). Simplicity of procedures: To facilitate collaboration, even in hospitals that suddenly become overloaded, patient enrolment (via the internet) and all other trial procedures are greatly streamlined. Informed consent is simple and data entry is minimal. Randomisation via the internet is simple and quick, at the end of which the allocated treatment is displayed on the screen and can be printed or downloaded. Follow-up information is recorded at a single timepoint and may be ascertained by contacting participants in person, by phone or electronically, or by review of medical records and databases. Page 1 of 39 RECOVERY [V12.1 2020-12-16] ISRCTN50189673 EudraCT 2020-001113-21 Data to be recorded: At randomisation, information will be collected on the identity of the randomising clinician and of the patient, age, sex, major co-morbidity, pregnancy, COVID- 19 onset date and severity, and any contraindications to the study treatments. The main outcomes will be death (with date and probable cause), discharge (with date), need for ventilation (with number of days recorded) and need for renal replacement therapy. Reminders will be sent if outcome data have not been recorded by 28 days after randomisation. Suspected Unexpected Serious Adverse Reactions (SUSARs) to one of the study medications (e.g., Stevens-Johnson syndrome, anaphylaxis, aplastic anaemia) will be collected and reported in an expedited fashion. Other adverse events will not be recorded but may be available through linkage to medical databases. Numbers to be randomised: The larger the number randomised the more accurate the results will be, but the numbers that can be randomised will depend critically on how large the epidemic becomes. If substantial numbers are hospitalised in the participating centres then it may be possible to randomise several thousand with mild disease and a few thousand with severe disease, but realistic, appropriate sample sizes could not be estimated at the start of the trial. Heterogeneity between populations: If sufficient numbers are studied, it may be possible to generate reliable evidence in certain patient groups (e.g. those with major co-morbidity or who are older). To this end, data from this study may be combined with data from other trials of treatments for COVID-19, such as those being planned by the WHO. Add-on studies: Particular countries or groups of hospitals, may well want to collaborate in adding further measurements or observations, such as serial virology, serial blood gases or chemistry, serial lung imaging, or serial documentation of other aspects of disease status. While well-organised additional research studies of the natural history of the disease or of the effects of the trial treatments could well be valuable (although the lack of placebo control may bias the assessment of subjective side-effects, such as gastro-intestinal problems), they are not core requirements. To enquire about the trial, contact the RECOVERY Central Coordinating Office Nuffield Department of Population Health, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom Tel: 0800 1385451 E-mail: [email protected] Website: www.recoverytrial.net To enquire about the trial outside of the UK, contact the relevant Clinical Trial Units (see section 10) To RANDOMISE a patient, visit: Website: www.recoverytrial.net Page 2 of 39 RECOVERY [V12.1 2020-12-16] ISRCTN50189673 EudraCT 2020-001113-21 Table of contents 1 BACKGROUND AND RATIONALE ................................................................................................ 4 1.1 SETTING .................................................................................................................................... 4 1.2 TREATMENT OPTIONS ................................................................................................................. 4 1.3 DESIGN CONSIDERATIONS .......................................................................................................... 6 1.4 POTENTIAL FOR EFFECTIVE TREATMENTS TO BECOME AVAILABLE .................................................. 6 2 DESIGN AND PROCEDURES ........................................................................................................ 7 2.1 ELIGIBILITY................................................................................................................................. 7 2.2 CONSENT ................................................................................................................................... 8 2.3 BASELINE INFORMATION.............................................................................................................. 8 2.4 MAIN RANDOMISATION ................................................................................................................ 9 2.5 SECOND RANDOMISATION FOR PATIENTS WITH PROGRESSIVE COVID-19 .................................... 10 2.6 ADMINISTRATION OF ALLOCATED TREATMENT ............................................................................. 12 2.7 COLLECTING FOLLOW-UP INFORMATION ..................................................................................... 12 2.8 DURATION OF FOLLOW-UP ........................................................................................................ 13 2.9 WITHDRAWAL OF CONSENT ....................................................................................................... 14 3 STATISTICAL ANALYSIS ............................................................................................................. 14 3.1 OUTCOMES .............................................................................................................................. 14 3.2 METHODS OF ANALYSIS ............................................................................................................ 15 4 DATA AND SAFETY MONITORING ............................................................................................. 16 4.1 RECORDING SUSPECTED SERIOUS ADVERSE REACTIONS .......................................................... 16 4.2 CENTRAL ASSESSMENT AND ONWARD REPORTING OF SUSARS .................................................. 16 4.3 RECORDING OTHER ADVERSE EVENTS ...................................................................................... 17 4.4 ROLE OF THE DATA MONITORING COMMITTEE (DMC) ................................................................ 17 4.5 BLINDING ................................................................................................................................. 17 5 QUALITY MANAGEMENT ...........................................................................................................

Load more

  39

Copy Link